Literature DB >> 9068393

Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease.

O D Pedersen1, J Gram, J Jespersen.   

Abstract

OBJECTIVE: To determine whether there was a relation between plasma resistance to activated protein C and the coagulation activation induced during thrombolysis with 100 mg alteplase in 25 patients with acute ischaemic heart disease.
METHODS: Blood samples were collected before (t = 0 h), during (t = 2.25 h), and after (t = 4 h, t = 12 h, and t = 24 h) thrombolysis to examine the relation between baseline activated protein C resistance ratio and markers of coagulation activation-that is, thrombinantithrombin III-complexes and prothrombin fragment 1 + 2 generated during thrombolysis.
RESULTS: There was a negative correlation between activated protein C resistance ratio and area under the curve of thrombin-antithrombin III-complexes (rs = - 0.60; P < 0.003) and there was a trend to a negative correlation between activated protein C resistance ratio and area under the curve of prothrombin fragment 1 + 2 (rs = - 0.37; P = 0.07). This accorded with the negative correlation between activated protein C resistance ratio and the peak value of thrombin-antithrombin III-complexes (rs = - 0.55; P < 0.005) and between activated protein C resistance ratio and the peak value of prothrombin fragment 1 + 2 (rs = - 0.42; P < 0.04). Components of the protein C/S system or known inhibitors of activated protein C may influence the activated protein C resistance ratio. There were no associations between the activated protein C resistance ratio and protein C, protein C inhibitor, or plasminogen activator inhibitor type-1, whereas there was a trend to a negative correlation between activated protein C resistance ratio and protein S.
CONCLUSIONS: The results indicate that plasma resistance to activated protein C may be one of the main mechanisms regulating the activation of coagulation induced by thrombolysis. This study suggests that it may be possible to single out individuals with a high risk of reocclusion before the start of thrombolytic therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9068393      PMCID: PMC484659          DOI: 10.1136/hrt.77.2.122

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  23 in total

1.  Generation of activated protein C during thrombolysis.

Authors:  A Gruber; A Pál; R G Kiss; G Sas; J H Griffin
Journal:  Lancet       Date:  1993-11-20       Impact factor: 79.321

Review 2.  Towards improved thrombolytic therapy.

Authors:  D Collen
Journal:  Lancet       Date:  1993-07-03       Impact factor: 79.321

3.  Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V.

Authors:  J S Greengard; S Eichinger; J H Griffin; K A Bauer
Journal:  N Engl J Med       Date:  1994-12-08       Impact factor: 91.245

4.  Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.

Authors:  B Zöller; P J Svensson; X He; B Dahlbäck
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

5.  Resistance to activated protein C as a basis for venous thrombosis.

Authors:  P J Svensson; B Dahlbäck
Journal:  N Engl J Med       Date:  1994-02-24       Impact factor: 91.245

6.  Mutation in blood coagulation factor V associated with resistance to activated protein C.

Authors:  R M Bertina; B P Koeleman; T Koster; F R Rosendaal; R J Dirven; H de Ronde; P A van der Velden; P H Reitsma
Journal:  Nature       Date:  1994-05-05       Impact factor: 49.962

7.  Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase.

Authors:  M Galvani; D R Abendschein; D Ferrini; F Ottani; F Rusticali; P R Eisenberg
Journal:  J Am Coll Cardiol       Date:  1994-11-15       Impact factor: 24.094

8.  New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group.

Authors:  W D Weaver; J R Hartmann; J L Anderson; P S Reddy; J C Sobolski; A A Sasahara
Journal:  J Am Coll Cardiol       Date:  1994-11-01       Impact factor: 24.094

9.  Reactive coagulation induced by plasmin in patients treated with recombinant tissue-type plasminogen activator.

Authors:  J Gram; S Munkvad; F W Leebeek; C Kluft; J Jespersen
Journal:  Coron Artery Dis       Date:  1993-04       Impact factor: 1.439

10.  Possible role of vascular intima for generation of coagulant activity in patients undergoing coronary thrombolysis with recombinant tissue-type plasminogen activator. A randomized, placebo-controlled study.

Authors:  S Munkvad; J Gram; J Jespersen
Journal:  Scand J Clin Lab Invest       Date:  1991-11       Impact factor: 1.713

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.